Source comparison
Front-Loading vs Maintenance: Actual Research Dosing Patterns
Clinical protocols for afamelanotide (the pharmaceutical form of MT-1) use front-loaded dosing: higher frequency administration during an induction phase, followed by either maintenance dosing or complete cessation depending on study objectives. The EU-approve
This comparison does not assign a generated winner or score.
- Clinical protocols for afamelanotide (the pharmaceutical form of MT-1) use front-loaded dosing: higher frequency administration during an induction phase, followed by either maintenance dosing or complete cessation depending on study objectives. The EU-approved protocol for erythropoietic protoporphyria uses subcutaneous implants delivering 16mg over 60 days. Effectively continuous low-level exposure. Australian dermatology trials studying photoprotection used daily subcutaneous injections of 0.16mg/kg for 10–14 days, then stopped entirely while monitoring pigmentation decay over 3–6 months.
- Neither approach resembles the '8 weeks on, 4 weeks off' pattern common to SARMs or the '5 days on, 2 days off' pattern used with some growth hormone secretagogues. The question isn't whether melanotan-1 can be cycled. It's whether cycling serves any biological purpose. In photoprotection research, the goal is sustained pigmentation across UV exposure seasons, which argues for continuous or pulsed dosing aligned with solar intensity rather than arbitrary on/off intervals. In experimental models studying melanocortin receptor signaling independent of pigmentation outcomes, there's no pharmacological rationale for washout periods between dosing blocks. We mean this sincerely: the cycling question is driven more by habits borrowed from other compound classes than by MT-1's actual pharmacology.